Navigation Links
Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Date:4/21/2008

SOUTH SAN FRANCISCO, Calif., April 21 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Thursday, May 1, 2008 at 4:30 p.m. (Eastern Time) to discuss first quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO of Monogram.

To participate in the live teleconference, please call (877) 545-1402, or (719) 325-4903 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through 11:59 p.m. (Eastern Time) on Thursday, May 15, 2008. The replay passcode is 4170582. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com and clicking on the Investor Relations link.

The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@ jeremiah.hall@

monogrambio.com fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
2. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
3. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
4. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
5. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
6. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
9. Monogram Announces Third Quarter 2007 Financial Results
10. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
(Date:2/23/2017)... , Feb. 23, 2017 Aviva ... tools, announced the acquisition of GenWay Biotech Incorporated, ... comprehensive service and product offering for both the ... will facilitate growth and enhance capabilities for both ... and ELISA assays will nicely complement ASB,s objective ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Park ... free AFM Luncheon for all SPIE attendees and Park customers ... just one block from the San Jose Convention Center. The luncheon will feature ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
Breaking Biology News(10 mins):